Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.

The breast journal - 1 May 2018

Bignon Lucie, Fricker Jean-Pierre, Nogues Catherine, Mouret-Fourme Emmanuelle, Stoppa-Lyonnet Dominique, Caron Olivier, Lortholary Alain, Faivre Laurence, Lasset Christine, Mari Veronique, Gesta Paul, Gladieff Laurence, Hamimi Akila, Petit Thierry, Velten Michel

Abstract excerpt

This study aims to estimate the pathologic complete response (pCR) rate after neo-adjuvant chemotherapy and to compare disease-free survival (DFS) and overall survival (OS) between pCR and non-pCR groups of patients with triple-negative breast cancer (TNBC) and deleterious BRCA1 or BRCA2 mutation. We carried out a retrospective analysis of 53 patients including 46 BRCA1, 6 BRCA2, and 1 combined BRCA1 and BRCA2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Disease-Free Survival

Share to Docetaxel

Share to Neoadjuvant Therapy

Share to Paclitaxel

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 28929593
DOI: 10.1111/tbj.12887

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.PMID 28929593Read ↗

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.Semantic proximity Read ↗

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.Semantic proximity Read ↗

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.Semantic proximity Read ↗

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - one clinic experience.Semantic proximity Read ↗

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.Semantic proximity Read ↗

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.Semantic proximity Read ↗

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.Semantic proximity Read ↗

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.Semantic proximity Read ↗

Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: A systematic review and meta-analysisSemantic proximity Read ↗

Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutationsSemantic proximity Read ↗

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.Semantic proximity Read ↗

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.